Check-Cap Reports Second Quarter 2020 Financial Results and

|Aug 6|magazine36 min read

ISFIYA, Israel, Aug. 6, 2020 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer, today announced financial results for the second quarter and six months ended June 30, 2020.

 

 

Second Quarter and Recent Highlights:

  • Strengthened balance sheet through gross proceeds of $16.3 million in registered direct offerings and a private placement of ordinary shares in the first half of 2020, followed by $9.6 million in a warrant exercise financing in July 2020. Company believes that it has sufficient capital to fund its ongoing operations and plans for at least the next 12 months.

 

  • Investigational Device Exemption (IDE) submission to the FDA planned for the end of 2020, with initiation of a U.S. pivotal study of C-Scan planned for 2021.

 

"I am happy with the progress we made during the first six months of 2020 and delighted to observe our team's commitment despite the ongoing global COVID-19 crisis. While some of the measures we took at the beginning of the pandemic slowed our anticipated progress, we have resumed near normal operations, including resuming ongoing collection of clinical data in Israel in the third quarter of 2020, and have been successfully adapting ourselves to the dynamic environment," said Alex Ovadia, chief executive officer of Check-Cap. "We anticipate IDE submission to the FDA by the end of 2020 and continue to refine and advance C-Scan to support initiation of a U.S. pivotal study in 2021. This includes establishing manufacturing capacity, quality infrastructure and collection of substantial additional data on device usability."

Mr. Ovadia added, "We have strengthened our ability to achieve corporate objectives with a total of $25.8 million raised during 2020. As a result, and despite these challenging times, we believe that we are well-positioned to fund our ongoing operations well into 2021, including our plans toward the initiation of the pivotal U.S. trial, while exploring partnerships with potential strategic industry leaders. There is a significant global unmet need for a non-invasive, preparation-free, colon cancer screening technology to detect polyps before they may transform into colorectal cancer, compared to colonoscopy which is the current standard of care. We truly believe the patient-friendly C-Scan system can increase screening rates globally by eliminating the rigorous and unpleasant preparation that colonoscopy and other tests require," said Alex Ovadia.

COVID-19 Corporate Update

In April 2020, as a consequence of the COVID-19 pandemic, the Company communicated it was taking necessary precautions to ensure the safety and well-being of its employees and their families in accordance with the directive of the Israel Ministry of Health, including enabling the majority of employees to work remotely and the remainder to continue working from the Company's headquarters. In parallel, the Company temporarily suspended interactions between hospitals and healthcare professionals with its employees and clinical trial patients and temporarily implemented several cost saving measures.

As a result of the lifting of many government restrictions to control the spread of COVID-19 and the Company's recent fundraisings, the Company resumed near normal operations including resuming its ongoing collection of clinical data in Israel in the third quarter of 2020 and it  continues to implement health and safety measures according to guidelines from the Israel Ministry of Health.

It is too early to assess the full impact of COVID-19, but COVID-19 has affected our ability to initiate our planned pivotal study and commence pilot sales in Israel and Europe in our original timeframe. The extent to which the COVID-19 pandemic impacts the Company's operations and planned timelines will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, the impact on the global economy, the impact of a second and any further waves of COVID-19 and the actions that may be required to contain the COVID-19 pandemic or treat its impact.

Financial Results for the Second Quarter Ended June 30, 2020

Research and development expenses were $2.1 million for the three months ended June 30, 2020, compared to $2.6 million for the same period in 2019. The decrease is primarily due to (i) a decrease of $0.3 million in clinical expenses mainly due to suspension of clinical activities in the second quarter of 2020 due to the COVID-19 pandemic, (ii) higher expenses for the pilot study in the U.S and post CE study in 2019, and (iii) a decrease of $0.2 million in other research and development expenses mainly due to several cost reduction measures implemented by the Company in the second quarter of 2020.

General and administrative expenses remained constant at $0.9 million for the three months ended June 30, 2020, and three months ended June 30, 2019.

Operating loss was $2.9 million for the three months ended June 30, 2020, compared to an operating loss of $3.5 million for the same period in 2019.

Net loss was $2.9 million for the three months ended June 30, 2020, compared to $3.4 million for the same period in 2019.

Cash and cash equivalents, restricted cash and short-term bank deposits totaled $16.4 million as of June 30, 2020, compared with $9.3 million as of March 31, 2020 and $8.0 million as of December 31, 2019. During the second quarter of 2020, the Company completed three registered direct offerings resulting in gross proceeds of $11.5 million (approximately $10.1 million net of offering expenses). Subsequent to the end of the second quarter, on July 27, 2020, the Company completed a warrant exercise financing resulting in gross proceeds of $9.6 million (approximately $8.7 million net of offering expenses). The Company believes that it has sufficient capital to fund its ongoing operations and plans for at least the next 12 months.

The number of outstanding ordinary shares as of June 30, 2020 was 30,172,943. As of August 4, 2020, the number of our outstanding ordinary shares was 46,231,661.

Financial Results for the Six Months Ended June 30, 2020

Research and development expenses were $4.5 million for the six months ended June 30, 2020, compared to $4.9 million for the same period in 2019. The decrease is primarily due to (i) a decrease of $0.5 million in clinical expenses mainly due to suspension of clinical activities in the second quarter of 2020 due to the COVID-19 pandemic, (ii) higher expenses for the pilot study in the U.S and post CE study in 2019, (iii) a decrease of $0.2 million in other research and development expenses mainly due to several cost reduction measures implemented by the Company in the second quarter of 2020, and (iv) a decrease of $0.2 million in share-based compensation. The foregoing decrease was offset in part by an increase of $0.4 million in salaries and related expenses as a result of an expansion in head count as compared to the same period in 2019.

General and administrative expenses were $1.9 million for the six months ended June 30, 2020, compared to $1.7 million for the same period in 2019. The increase was primarily due to an increase of $0.1 million in share-based compensation and $0.2 million in other general expenses, offset in part by a decrease of $0.1 million in professional services expenses.

Operating loss was $6.4 million for the six months ended June 30, 2020, compared to $6.7 million in the same period in 2019.

Net loss was $6.3 million for the six months ended June 30, 2020, compared to $6.5 million for the same period in 2019.

Net cash used in operating activities was $6.4 million for the six months ended June 30, 2020, compared to Net cash used in operating activities of $6.3 million for the same period in 2019.

            [Financial Tables to Follow]

About Check-Cap

Check-Cap is a clinical stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening and prevention through the introduction of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer. The Company's disruptive capsule-based screening technology aims to significantly increase screening adherence worldwide and help millions of people to stay healthy through preventive CRC screening. C-Scan uses an ultra-low dose X-ray capsule, an integrated positioning, control and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon. C-Scan is non-invasive and requires no preparation or sedation, allowing the patients to continue their daily routine with no interruption as the capsule is propelled through the gastrointestinal tract by natural motility.

Legal Notice Regarding Forward-Looking Statements

This press release contains "forward-looking statements." Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Forward-looking Statements" and "Risk Factors" in the Company's Annual Report on Form 20-F for the year ended December 31, 2019 and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

 

 

CHECK CAP LTD


CONSOLIDATED UNAUDITED BALANCE SHEETS

(U.S. dollars in thousands, except share and per share data)







June 30,


December 31







2020


2019












Assets














Current assets






Cash and cash equivalents

8,390


7,685



Restricted cash

350


350



Short-term bank deposit

7,656


-



Prepaid expenses and other current assets

503


400



Total current assets

16,899


8,435











Non-current assets






Property and equipment, net

630


540



Operating leases

347


454



Total non-current assets

977


994



Total assets

17,876


9,429



















Liabilities and shareholders' equity














Current liabilities






Accounts payable and accruals






Trade

643


989



Other

258


490



Employees and payroll accruals

1,471


1,101



Operating lease liabilities

204


222



Total current liabilities

2,576


2,802



















Non-current liabilities






Royalties provision

177


182



Operating lease liabilities

121


211



Total non-current liabilities

298


393











Shareholders' equity







Share capital, Ordinary shares, 2.4 NIS par value (90,000,000 authorized shares as of
June 30, 2020 and December 31, 2019, respectively; 30,172,943 and 8,272,908 shares
issued and outstanding as of June 30, 2020 and December 31, 2019, respectively)

20,348


5,407



Additional paid-in capital

78,110


77,964



Accumulated deficit

(83,456)


(77,137)



Total shareholders' equity

15,002


6,234











Total liabilities and shareholders' equity

17,876


9,429











 

 

CHECK CAP LTD


CONSOLIDATED UNAUDITED STATEMENTS OF COMPREHENSIVE LOSS

(U.S. dollars in thousands, except share and per share data)




Six months ended June 30,

Three months ended June 30,




2020


2019


2020

2019











Research and development expenses, net

4,513


4,909


2,051

2,570



General and administrative expenses

1,855


1,749


898

924



Operating loss

6,368


6,658


2,949

3,494











Finance income, net

49


153


61

139



Loss before income tax

6,319


6,505


2,888

3,355



Taxes on income

-


-


-

-



Net loss

6,319


6,505


2,888

3,355



















Other comprehensive loss:

















Change in fair value of cash flow hedge

-


13


-

(4)



Comprehensive loss

6,319


6,518


2,888

3,351











Net loss per ordinary share - basic and diluted

0.38


0.85


0.12

0.41











Weighted average number of ordinary shares outstanding
- basic and diluted

16,676,469


7,663,045


23,396,152

8,238,034











 

 

 

CHECK CAP LTD.

CONSOLIDATED UNAUDITED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

(U.S. dollars in thousands, except share and per share data)



Number of


Additional

Other


Total


Ordinary


paid-in

comprehensive

Accumulated

shareholders'


Shares

Amount

capital

loss

deficit

equity








Balance as of January 1, 2020

8,272,908

$

5,407

$

77,964

$

-

$

(77,137)

$

6,234

Issuance of ordinary shares in private


















placement, net of issuance expenses in


















an amount of approximately $30

2,720,178


1,894


2,837


-


-


4,731

RSU vesting

6,633


4


(4)








-

Share-based compensation

-


-


123


-


-


123

Net loss

-


-


-


-


(3,431)


(3,431)

Balance as of March 31, 2020

10,999,719

$

7,305

$

80,920


-

$

(80,568)

$

7,657

Issuance of ordinary shares and warrants in
the April – May 2020 Financings, net of
issuance












expenses in an amount of $1,361

19,166,670

$

13,039

$

(2,900)


-


-

$

10,139

RSU vesting

6,554

$

4


(4)






-

Share-based compensation

-


-

$

94


-



$

94

Net loss

-


-


-


-

$

(2,888)

$

(2,888)

Balance as of June 30, 2020

30,172,943

$

20,348

$

78,110

$

-

$

(83,456)

$

15,002













Balance as of January 1, 2019

5,330,684

$

3,456

$

72,888

$

(13)

$

(63,301)

$

13,030

Issuance of ordinary shares and warrants in
the 2019












registered direct offering, net of issuance












expenses in an amount of $987

2,906,376


1,928


4,583


-


-


6,511

RSU vesting

718


(*)


-






(*)

Share-based compensation

-


-


83


-


-


83

Other comprehensive loss

-


-


-


17


-


17

Net loss

-


-


-


-


(3,150)


(3,150)

Balance as of March 31, 2019

8,237,778


5,384


77,554


4


(66,451)


16,491

Share-based compensation

-




186






186

RSU vesting

684


(*)


-


-


-


(*)

Other comprehensive loss

-


-


-


(4)


-


(4)

Net loss

-


-


-


-


(3,355)


(3,355)

Balance as of June 30, 2019

8,238,462


5,384


77,740


-


(69,806)


13,318

























                              (*)  Represents amount less than 1 thousand.





 

 


CHECK-CAP LTD.






CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS



(U.S. dollars in thousands, except share and per share data)







Six months ended




June 30




2020


2019



CASH FLOWS FROM OPERATING ACTIVITIES








Net loss for the period

(6,319)


(6,505)



Adjustments required to reconcile net loss to net cash used in operating activities:








Depreciation

68


55



Share-based compensation

217


269



Financial (income) expenses, net

(14)


(32)



Changes in assets and liabilities items:








Decrease (increase) in prepaid and other current assets and non-current assets

(100)


50



Increase (decrease) in trade accounts payable, accruals and other current liabilities

(591)


(204)



Increase (decrease) in employees and payroll accruals

370


15



Increase (decrease) in royalties provision

(5)


3



Net cash used in operating activities

(6,374)


(6,349)










CASH FLOWS FROM INVESTING ACTIVITIES








Purchase of property and equipment

(140)


(49)



Proceeds from (investment in) short-term bank and other deposit

(7,651)


(370)



Net cash used in investing activities

(7,791)


(419)










CASH FLOWS FROM FINANCING ACTIVITIES








Issuance of ordinary shares and warrants in the 2019 registered direct offering, net of issuance expenses

-


6,511



Issuance of ordinary shares in the private placement, net of issuance expenses

4,731


-



Issuance of ordinary shares and warrants in the 2020 registered direct offerings, net of issuance expenses

10,139





Net cash provided by financing activities

14,870


6,511








Net increase (decrease) in cash, cash equivalents and restricted cash

705


(257)



Cash, cash equivalents and restricted cash at the beginning of the period

8,035


8,922



Cash, cash equivalents and restricted cash at the end of the period

8,740


8,665


 

 





CHECK-CAP LTD.





CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS





(U.S. dollars in thousands, except share and per share data)










                                                  Supplemental information for Cash Flow:






Six






months






ended






June






30,






2020

2019





Supplemental disclosure of non-cash flow information







Purchase of property and equipment included in accounts payable and accrued expenses

15

-





     Recognition of operating leases and operating lease liabilities from adoption of ASU 2016-02

-

490





 

 

Investor Contacts

Irina Koffler
LifeSci Advisors, LLC
646.970.4681
[email protected]

Meirav Gomeh-Bauer
LifeSci Advisors, LLC
+972(0)-54-476-4979  
[email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/check-cap-reports-second-quarter-2020-financial-results-and-corporate-highlights-301107569.html

SOURCE Check-Cap Ltd.